Rivenprost
Based on 1 Customer Validation
Rivenprost (ONO-4819; ONO-AE1-734) is a selective agonist for prostaglandin E receptor EP4 with Ki of 0.7 nM. Rivenprost exhibits hepatoprotective and bone anabolic effects.
For research use only. We do not sell to patients.
- Purity: 99.0%
- CAS No.: 256382-08-8
- Formula: C24H34O6S
- Molecular Weight:450.59
-
Storage:
Solution, -20°C, 2 years
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
EP4 0.7 nM (Ki) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
1.6 nM
Compound: 52, ONO-4819
|
Agonist activity at mouse EP4 receptor expressed in CHO cells assessed as cAMP production
Agonist activity at mouse EP4 receptor expressed in CHO cells assessed as cAMP production
|
[PMID: 20218623] |
Rivenprost (1 nM–1 μM) stimulates the osteoblast differentiation through upregulation of Runx2 and Osterix, leading to increased bone formation[1].
Rivenprost (1 nM–1 μM) inhibits the adipocytes differentation in bone by downregulating the mRNA expression of PPARγ[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:C3H10T1/2
-
Concentration:1 nM–1 μM
-
Incubation Time:7 days
-
Result:Reduced PPARγ in a dose-dependent manner.
Rivenprost (0.2 mg/kg, i.p., single dosage) exhibits hepatoprotective efficacy towards GalN-/LPS-induced liver injury in wistar rats through inflammatory cytokines such as TNF-α[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley rats[1]
-
Dosage:10 μg/kg
-
Administration:s.c., twice a day for 5 weeks
-
Result:Increased osteoblast number, bone volume, mineral apposition rate and bone formation rate.
Decreased adipocyte number.
-
Animal Model:GalN/LPS-induced acute liver injury in wistar rats[2]
-
Dosage:0.2 mg/kg
-
Administration:i.p., single dosage
-
Result:Inhibited development of hepatic necrosis, decreased levels of AST, ALT, TNF-α and IFN-γ.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 256382-08-8
-
Appearance Liquid
-
Molecular Weight 450.59
-
Formula C24H34O6S
-
Color Colorless to light yellow
-
SMILES
COCC1=CC=CC(C[C@H](O)/C=C/[C@@H]2[C@H](C(C[C@H]2O)=O)CCSCCCC(OC)=O)=C1
-
Synonyms
ONO-4819; ONO-AE1-734
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Solution, -20°C, 2 years
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ninomiya T, et al., Prostaglandin E(2) receptor EP(4)-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation. Eur J Pharmacol. 2011 Jan 10;650(1):396-402. [Content Brief]
[2]. Kasai K, et al., A novel prostaglandin E receptor subtype agonist, 0N0-4819, attenuates acute experimental liver injury in rats. Hepatol Res. 2001 Nov;21(3):252-260. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Rivenprost Related Classifications
HY-114974 Related Classifications
Powered by Bioz